

This article was downloaded by:

On: 30 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Spectroscopy Letters

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597299>

NMR Studies Of Drugs. Chiral Solvating Agents for Direct Determination of Enantiomeric Excess of the Cardiac Antiarrhythmic, Mexiletine

Hassan Y. Aboul-Enein^a; Robert Rothchild^b; Anton Sinnema^c

^a Drug Development Laboratory, Radionuclide and Cyclotron Operations, King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia ^b Science Department, Toxicology Research and Training Center, The City University of New York John Jay College of Criminal Justice, New York, NY ^c Laboratory of Organic Chemistry and Catalysis, Delft University of Technology, Faculty of Chemical Technology and Materials Science, BL Delft, The Netherlands

To cite this Article Aboul-Enein, Hassan Y. , Rothchild, Robert and Sinnema, Anton(1992) 'NMR Studies Of Drugs. Chiral Solvating Agents for Direct Determination of Enantiomeric Excess of the Cardiac Antiarrhythmic, Mexiletine', Spectroscopy Letters, 25: 8, 1367 — 1385

To link to this Article: DOI: 10.1080/00387019208017870

URL: <http://dx.doi.org/10.1080/00387019208017870>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NMR STUDIES OF DRUGS. CHIRAL SOLVATING AGENTS FOR
DIRECT DETERMINATION OF ENANTIOMERIC EXCESS OF THE
CARDIAC ANTIARRHYTHMIC, MEXILETINE.

Key Words: Optical Purity, Enantiomer, Analysis,
1-(2,6-Dimethylphenoxy)-2-propanamine,
Antiarrhythmic, Cyclodextrin, α -Methoxy- α -
(trifluoromethyl)phenylacetic acid, MTPA, 2,2,2-
Trifluoro-1-(9-anthryl)ethanol, TFAE.

*Hassan Y. Aboul-Enein^a, Robert Rothchild^b, and
Anton Sinnema^c

- a) Drug Development Laboratory, Radionuclide and Cyclotron Operations, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Kingdom of Saudi Arabia;
- b) The City University of New York, John Jay College of Criminal Justice, Science Department, Toxicology Research and Training Center, 445 West 59th Street, New York NY 10019-1199;
- c) Delft University of Technology, Faculty of Chemical Technology and Materials Science, Laboratory of Organic Chemistry and Catalysis, Julianalaan 136, 2628 BL Delft, The Netherlands.


* Author to whom correspondence should be sent.

ABSTRACT

The 400 MHz ^1H NMR spectra of the cardiac antiarrhythmic, mexiletine, 1, have been studied with different chiral solvating agents (CSA) to obtain a very promising method for direct determination of enantiomeric excess (e.e.) with limited amounts of 1. The methods included the use of β -cyclodextrin (β -CD), γ -cyclodextrin (γ -CD), α -methoxy- α -(trifluoromethyl)phenylacetic acid (MTPA), and 2,2,2-trifluoro-1-(9-anthryl)ethanol (TFAE). Use of TFAE in CDCl_3 with the free base of 1 appeared to give the best results, with enantiomeric shift differences observed for the signals of the sidechain methyl, CH_3CH , and the aryl methyls.

INTRODUCTION

Mexiletine, 1-(2,6-dimethylphenoxy)-2-propanamine, 1, has antiarrhythmic activity. Both enantiomers have been obtained as (R)-(-)-1 and (S)-(+)-1 and the pharmacokinetics of the enantiomers in humans have been studied; the stereoselective disposition of 1 has been reported (1-4) as well as aspects of stereospecific binding (5,6). Various analytical techniques have been applied for enantiomeric excess (e.e.)



determination of 1, including: (a) high performance liquid chromatography (HPLC) of diastereomers after use of a chiral derivatizing reagent (1) or with a chiral stationary phase (CSP) (2,4,6-8); (b) capillary column gas chromatography (GC) with a CSP (9). All of these analyses required prior derivatization of 1 for subsequent chromatography, either with achiral (2,4,6-9) or chiral (1) reagents. In addition, one non-chromatographic method has been described, based on ^1H NMR spectroscopy using chiral lanthanide shift reagents (LSR) (10). The NMR LSR technique has the advantage of being a true direct analysis, with no separate derivatization step required. However, because this earlier NMR LSR method employed a low field 60 MHz spectrometer, relatively large amounts of sample were required, ca. 40-60 mg. It was therefore of interest to extend the NMR studies for direct e.e. determination of 1 using a higher field

(400 MHz) NMR spectrometer for analyses at the level of a few milligrams or less. The techniques employed in this present work were based on the use of chiral solvating agents (CSA). In addition to elaboration of a direct NMR method using CSA for potential e.e. determinations of 1, a non-racemic sample of 1 was analyzed to determine the sense of induced magnetic nonequivalence for the two enantiomers.

NMR methods for e.e. determinations based on chiral solvating agents have been reviewed (11,12). The most attractive of these CSAs appeared to be based on the use of a trifluoromethylarylcabbinol to form short-lived diastereomeric solvates with the substrate. The carbinol CSAs, being more acidic than related amine CSAs, were considered to be more appropriate for use with a basic substrate such as 1 (13-15). Thus, studies were performed using (-)-2,2,2-trifluoro-1-(9-anthryl)ethanol, TFAE (14).

In addition, parallel studies were explored using other CSA techniques. Cyclodextrins have been found useful in allowing NMR discrimination of pharmaceutical enantiomers via formation of the inclusion complexes (16). Both β -cyclodextrin (β -

CD) and γ -cyclodextrin (γ -CD) were employed to explore different cavity sizes. Lastly, α -methoxy- α -(trifluoromethyl)phenylacetic acid, MTPA, was briefly examined as a chiral complexing agent for 1. MTPA amides and esters have been used as covalently bound diastereomeric derivatives of amines and alcohols, respectively, to allow e.e. determination by NMR or chromatography (17,18). We considered a modification using MTPA as a complexation reagent via salt formation (19).

EXPERIMENTAL

All spectra were acquired on a Varian VXR-400S FT-NMR spectrometer with a ^1H observe frequency of 399.952 MHz, using a 5mm switchable ^1H /broadband (80-160 MHz) probe, thin-walled NMR tubes and a 25° probe temperature. Typical spectrometer parameters were: 30° pulse flip angle, 5s pulse repetition time, 3s acquisition time, 32 acquisitions, 4317.8 Hz spectral width, 25984 datapoints (32 bits), and 0.05 Hz exponential line broadening. Solutions were prepared in 1.0 ± 0.1 ml CDCl_3 (unless otherwise noted) and used 0.03% tetramethylsilane (TMS) as internal reference ($\delta = 0.000$). For samples requiring the free base of 1, the hydrochloride salts (1-HCl) were dissolved in a few

ml H₂O, and 2M NaOH was added to give pH ca. 12. After extraction with four portions CHCl₃, the combined CHCl₃ extracts were dried (anhyd. K₂CO₃) and the solvent evaporated. The residue was then taken up in CDCl₃, and dried (K₂CO₃). Evaporation of the solvent gave the free base, 1, which was used directly for NMR studies. Commercial reagents were used as supplied without further purification. Deuterium oxide (99.8 atom % D) and deuteriochloroform (99.8 atom % D, containing 0.03% TMS) were from Janssen Chimica, Belgium; mexiletine samples were from Boehringer, Germany; (R)-(-)-TFAE (98%), MTPA, and δ -cyclodextrin were from Aldrich Chemical Co., Milwaukee WI, USA; β -cyclodextrin was from Sigma Chemical Co., USA. For the "spiked" run of non-racemic 1 with (R)-(-)-TFAE, a portion of (-)-1-HCl was converted to the free base (as described above) which was added to a CDCl₃ solution of racemic free base 1. Chemical shifts are reported in ppm; where enantiomeric shift differences were observed, the average chemical shift for the two antipodes is given.

RESULTS AND DISCUSSION

When increments of (-)-TFAE were added to a solution of racemic mexiletine free base in CDCl₃,




Fig. 1. Variation in enantiomeric shift difference, $\Delta\delta$ (in ppb), with molar ratio $[\text{TFAE}]/[1]$ for a solution of l ca. 0.0305 molal in CDCl_3 at 25° . Data is shown for the CH_3CH signal.

at 25° , enantiomeric shift differences ($\Delta\delta$) were observed for both the CH_3CH methyl doublet signals and for the methyl singlet signals of the 2,6-dimethylphenyl moiety. The $\Delta\delta$ magnitudes were appreciably greater for the former signal. The variation of $\Delta\delta$ with molar ratio of $(-)\text{-TFAE}/\text{l}$ for the CH_3CH resonance is shown in Figure 1 and




Fig. 2. Expansions of the 400 MHz ^1H NMR of 1 with added (-)-TFAE. For each trace, the following is specified: observed nucleus; average chemical shift (δ , ppm); enantiomeric shift difference ($\Delta\delta$, Hz); molar ratio of (-)-TFAE to total 1. (a) CH_3CH ; 1.096 ppm; 3.56 Hz; 0.744; (b) CH_3CH ; 0.830 ppm; 8.70 Hz; 7.88; (c) $(\text{CH}_3)_2\text{C}_6\text{H}_3$; 2.030 ppm; 4.8 Hz; 7.88; (d) CH_3CH ; 0.847 ppm; 8.44 Hz; (e) $(\text{CH}_3)_2\text{C}_6\text{H}_3$; 2.042 ppm; 3.6 Hz. Note: traces (d) and (e) were obtained from solution of Fig. 2b, above, by spiking with (-)-1.

representative spectral traces in Figure 2. The development of $\Delta\delta$ is accompanied by slight upfield shifts for both the CH_3CH and aryl methyl signals. A non-racemic sample of 1 free base was prepared by

"spiking" racemic material with $(-)\text{-1}$, and this mixture was subjected to treatment with $(-)\text{-TFAE}$. Under these conditions, the lower field doublet of the CH_3CH signals was enhanced, i.e., the doublet shifted upfield more slowly must be due to $(-)\text{-1}$. Thus, for the sidechain CH_3CH with $(-)\text{-TFAE}$ added, $(-)\text{-1}$ has a downfield sense of magnetic nonequivalence (see Fig. 2).

In contrast, the higher field aryl methyl signal was enhanced for the spiked sample, so that an upfield sense of magnetic nonequivalence results for $(-)\text{-1}$ with added $(-)\text{-TFAE}$. The fact that opposite senses of magnetic nonequivalence are seen for the CH_3CH versus the aryl CH_3 signals means that the enantiomeric shift differences may reflect not simply a preferential binding of one of the enantiomers of 1 to the TFAE, but also geometric differences of the locations of the marker nuclei in the diastereomeric solvates. Finally, we note that the unequal peak intensities for the aryl methyl signal in non-racemic 1 with $(-)\text{-TFAE}$ confirms that the observed peak separations result from true enantiomeric shift differences (rather than from hypothetically nonequivalent methyl groups on the aromatic ring due to slow rotation of the ring on the NMR timescale).

Even relatively small amounts of (-)-TFAE can be effective. With racemic 1 (0.0305 molal in CDCl_3) and a molar ratio $[\text{TFAE}]/[\underline{1}]$ of 0.744, average $\Delta\delta$ of 3.56 Hz (9.2 ppb) was seen for the CH_3CH signals. Although each enantiomer's doublet was overlapped, the average valley heights between peaks of each antipode (i.e., the two low field lines or the two high field lines) was just over 10%.

For racemic 1 in CDCl_3 at a molar ratio of $[\text{TFAE}]/[\underline{1}]$ of ca. 7.88 (the highest examined), a $\Delta\delta$ magnitude of about 12 ppb was observed for the aromatic methyl signal versus 21.7 ppb for the sidechain CH_3CH . Under our conditions, the valley height between the aryl methyl signals was about 11% of the average peak heights from the two enantiomers, as shown in Fig. 2. Since the CH_3CH signal is a 3H intensity doublet (in the absence of CSA) and the ArCH_3 a 6H singlet, the lines of the aromatic methyl signals are each four times as intense as those for the sidechain methyl. (Actually, the full peak height advantage of the aromatic methyl signal is not realized since its linewidth is greater than for the CH_3CH peaks, presumably caused by long-range coupling to aryl

protons). Particularly in cases where only very small amounts of 1 are available, e.e. determinations using the aromatic methyl signals may be preferred despite their smaller $\Delta\delta$ magnitude. Alternative approaches to the direct e.e. determination using TFAE and the CH₃CH signals are described below.

Enantiomeric excess determinations for some pharmaceuticals by NMR of cyclodextrin inclusion complexes in D₂O appeared to be a promising technique (16). We examined racemic 1 as its HCl salt in D₂O using β -CD as CSA. The limited success may partly reflect the limited water solubility of β -CD (20). The largest $\Delta\delta$ magnitudes were again found for the sidechain methyl of 1, CH₃CH. For example, with 1.09 mg racemic 1-HCl in 1.0 ml D₂O, observed average $\Delta\delta$ values were only 2.68 Hz (6.7 ppb) with 28.4 mg β -CD added; using 56.8 mg β -CD, the observed $\Delta\delta$ was actually less: 2.19 Hz (5.5 ppb). (The actual amount of added β -CD is nominal since both of these solutions required filtration. Solutions with lower levels of the CSA were homogeneous but $\Delta\delta$ magnitudes were smaller). Thus, the $\Delta\delta$ magnitudes were much smaller than the vicinal coupling constant and the doublets for each

enantiomer's CH_3CH signal were severely overlapped. The valley heights between adjacent lines from the two antipodes were quite high, about 43% and 48%, respectively, for the samples noted above with 28.4 and 56.8 mg of added β -CD. No discernible $\Delta\delta$ was seen for the aryl methyls at any level of this cyclodextrin CSA. Very small downfield shifts were induced for both of the methyl signals with added β -CD.

We considered the possibility that the 2,6-dimethylphenyl moiety of 1 was too large to be fully accommodated within the hydrophobic interior of the β -CD cavity. Examination of Dreiding models suggested that ca. 6.6\AA would be needed for the dimethylphenyl group based on the distance between the methyl groups (21). The cavity diameter for β -CD has been estimated at $6.0\text{--}6.5\text{\AA}$ (20) with 7.8\AA maximum diameter. If optimal enantiomeric shift difference is dependent upon the substrate's chiral center and analytical "reporter" nuclei both being close to the chiral hydroxyl group environment at the mouth of the CD cavity, this might require a greater penetration into the CD cavity by the hydrophobic dimethylphenyl moiety of 1 than physical size allows. In contrast, γ -CD has a more

spacious cavity, with estimated diameter of 7.5-8.3 Å and 9.5 Å maximum diameter (20). This would certainly allow full penetration by the hydrophobic portion of 1. In addition, γ -CD has more than twelve times the water solubility of β -CD, 23.2 versus 1.85 g/100 ml at 25° (20), and it was thought that this might prove advantageous by allowing higher molar ratios of CSA:1. However, when γ -CD was tried, $\Delta\delta$ values were far inferior to those seen with β -CD. It may be that the fit of 1 in the larger cavity was simply too floppy, and that 1 in the smaller cavity of β -CD provided a more desirable tighter fit, even though the dimethylphenyl moiety may not have been fully within the cavity; this must be considered speculative.

Use of MTPA as a CSA for NMR e.e. determination of amines has been described (19). We attempted to examine racemic 1 free base in $CDCl_3$ with added (+)-MTPA. In our hands, presumed salt formation led to precipitation from the solution, preventing spectral acquisition. This approach was not pursued further.

Of the different CSAs tried, TFAE appeared most useful. Using this reagent, we examined the




Fig. 3. Spectral deconvolutions of traces from Fig. 2a and Fig. 2b, above. For each deconvolution, (a) and (b), respectively, the uppermost trace is the actual spectrum, the center trace is the full fit, and the bottom trace shows the individual component plots. See caption for Fig. 2 for sample conditions.

use of the CH_3CH doublet signals (which exhibited the largest $\Delta\delta$ values) with the ancillary technique of spectral deconvolution by means of the standard Varian software, applying Lorentzian line-shapes. Deconvoluted spectra are shown in Figure 3. This method appeared to offer considerable promise for e.e. quantitation of the doublet signals (which are not baseline resolved). The deconvolutions appear to be excellent fits to the experimental spectra and suggest the possibility of e.e. determinations with substantially less TFAE than would be necessary for complete separation of the doublet signals. Homonuclear decoupling via selective irradiation of the methine CH_3CH to collapse the methyl doublets to singlets was also considered. But experimentally, complete decoupling was not achievable due to the extreme widths of the multiplets caused by extensive couplings and differential induced chemical shifts.

CONCLUSIONS

Different CSAs have been examined for use in the direct e.e. determination of mexiletine. The best results (largest $\Delta\delta$ magnitudes and smallest valley heights) were achieved with 1 free base in CDCl_3 using (-)-TFAE, based on the CH_3CH signal.

The (-) enantiomer of 1 exhibited a downfield sense of magnetic nonequivalence. We estimate that, for practical applications, a single milligram each of mexiletine sample and (-)-TFAE are sufficient for e.e. analysis with a 400 MHz (or higher frequency) spectrometer. Good results were also seen using the aryl methyl signals. Spectral deconvolution promised even greater potential. Use of β -CD in D_2O with 1-HCl was inferior, with smaller $\Delta\delta$ magnitudes and higher valley heights; γ -CD was still less effective. Use of MTPA with 1 free base in $CDCl_3$ caused precipitation and could not be applied.

ACKNOWLEDGMENTS

This work was supported, in part, by the National Science Foundation Instrumentation and Laboratory Improvement Program grants no. USE-9152822 and USE-8851684, U.S. Education Department Minority Science Improvement Program grant no. G-008641165, Hewlett-Packard Corp. grant no. 0017-80769, U.S. Department of Energy ERLE grants no. AL-90-092 and AL-89-169, Hoffmann-LaRoche Inc., Berlex Laboratories, Inc. and the Forty-Five Foundation (to R.R.) One of the authors (HYAE) thanks the Administration of King Faisal Specialist

Hospital and Research Centre for their continuous support of the Drug Development Research Program. The authors thank Boehringer Ingelheim KG, Germany, for providing samples of racemic mexiletine hydrochloride and the corresponding enantiomers used in this study.

LITERATURE REFERENCES

1. Grech-Belanger O., Turgeon J., Gilbert M. High performance liquid chromatographic assay for mexiletine enantiomers in human plasma. *J. Chromatogr.* 1985; 337(1): 172-177.
2. McErlane K.M., Igwemezie L., Kerr C.R. Stereoselective analysis of the enantiomers of mexiletine by high performance liquid chromatography using fluorescence detection and study of their stereoselective disposition in man. *J. Chromatogr.* 1987; 415(2): 335-346.
3. Grech-Belanger O., Turgeon J., Gilbert M. Stereoselective disposition of mexiletine in man. *Br. J. Clin. Pharmacol.* 1986; 21(5): 481-487.
4. Igwemezie L., Kerr C.R., McErlane K.M. The pharmacokinetics of the enantiomers of mexiletine in humans. *Xenobiotica* 1989; 19(6): 677-682.
5. Hill R.J., Duff H.J., Sheldon R.S. Determinants of stereospecific binding of type I antiarrhythmic drugs to cardiac sodium channels. *Mol. Pharmacol.* 1988; 34(5): 659-663.
6. McErlane K.M., Igwemezie L., Kerr C.R. Stereoselective serum protein binding of mexiletine enantiomers in man. *Res. Commun. Chem. Pathol. Pharmacol.* 1987; 56(1): 141-144.
7. Yang Q., Sun Z.P. The application of Pirkle-type chiral column to the resolution of enantiomeric drugs: Resolution of some amines and

- alcohols using α -naphthyl isocyanate. *Acta Pharmaceutica Sinica* (Yaoxue Xuebao) 1988; 23(11): 921-926. *Chem Abstr.* 1989; 110: 219195r.
8. Weller O., Schulze J., König W.A. Separation of racemic pharmaceuticals by high performance liquid chromatography on silica gel modified with carbohydrate residues. *J. Chromatogr.* 1987; 403: 263-270.
9. König W.A., Lutz S., Wenz G., Von der Bey E. Cyclodextrins as chiral stationary phases in capillary gas chromatography. Part II: heptakis(3-O-acetyl-2,6-di-O-pentyl)- β -cyclodextrin. *HRC CC, J. High Resolut. Chromatogr. Chromatogr. Commun.* 1988; 11(7): 506-509.
10. Aboul-Enein H.-Y., Médonné S., Rothchild R. ^1H NMR spectral simplification with achiral and chiral lanthanide shift reagents. Mexiletine. *Spectrosc. Lett.* 1991; 24(6): 909-930.
11. Pirkle W.H., Hoover D.J. NMR chiral solvating agents. In: Eliel E.L., Allinger N.L., Wilen S.H., eds. *Topics in Stereochemistry*, vol. 13. New York: Wiley-Interscience 1982; 263-331 and references therein.
12. Weisman G.R. Nuclear magnetic resonance analysis using chiral solvating agents. In: Morrison J.D. ed. *Asymmetric Synthesis*, vol. 1. New York, London: Academic Press 1983; 153-171.
13. Pirkle W.H., Burlingame T.G., Beare S.D. Optically active NMR solvents. VI. Determination of optical purity and absolute configuration of amines. *Tetrahedron Lett.* 1968; (56): 5849-5852.
14. Pirkle W.H., Sikkenga D.L., Pavlin M.S. Nuclear magnetic resonance determination of enantiomeric composition and absolute configuration of γ -lactones using chiral 2,2,2-trifluoro-1-(9-anthryl)ethanol. *J. Org. Chem.* 1977; 42(2): 384-387.
15. Pirkle W.H., Hauske J.R. Design of chiral derivatizing agents for the chromatographic resolution of optical isomers. Asymmetric synthesis of some chiral fluoroalkylated amines. *J. Org. Chem.* 1977; 42(14): 2436-2439.

16. Casy A.F., Mercer A.D. Application of cyclodextrins to chiral analysis by ^1H NMR spectroscopy. *Magn. Reson. Chem.* 1988; 26(9): 765-774.
17. Dale J.A., Dull D.L., Mosher H.S. α -Methoxy- α -trifluoromethylphenylacetic acid, a versatile reagent for the determination of enantiomeric composition of alcohols and amines. *J. Org. Chem.* 1969; 34(9):2543-2549.
18. Dale J.A., Mosher H.S. Nuclear magnetic resonance enantiomer reagents. Configurational correlations via nuclear magnetic resonance chemical shifts of diastereomeric mandelate, O -methylmandelate, and α -methoxy- α -trifluoromethyl phenylacetate (MTPA) esters. *J. Am. Chem. Soc.* 1973; 95(2): 512-519.
19. Villani, Jr., F.J., Costanzo M.J., Inners R.R., Mutter M.S., McClure D.E. Determination of enantiomeric purity of tertiary amines by ^1H NMR of α -methoxy- α -(trifluoromethyl)phenylacetic acid complexes. *J. Org. Chem.* 1986; 51(19): 3715-3718.
20. Schurig V., Nowotny H.-P. Gas chromatographic separation of enantiomers on cyclodextrin derivatives. *Ang. Chem. Int. Ed. Engl.* 1990; 29(9): 939-957.
21. Dreiding models, Brinkmann Instruments Co., Westbury N.Y.

Date Received: 06/19/92
Date Accepted: 07/24/92